Revolutionizing Hematologic Cancer Treatment: The Promise of Bispecific T-Cell Engagers

Bispecific T-cell engagers are emerging as promising treatment options for patients with heavily pretreated multiple myeloma and B-cell lymphomas, especially for patients with disease relapse following CAR T-cell therapy. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit associated with bispecific T-cell engager therapy. There is a clear need to educate clinicians about the special considerations associated with the use of bispecific T-cell engagers in appropriately selected patients. Expert-led education will help clinicians to integrate this novel treatment option safely into their routine clinical practice.

Target Audience

This educational program is designed to meet the educational needs of oncologists, hematologists, nurse practitioners, nurses, pharmacists, physician assistants, and other health care professionals who manage patients with hematologic malignancies.

Learning Objectives

Following this program, participants should be able to:

  • Describe the mechanism of action of bispecific T-cell engagers and the rationale for their use in the treatment of patients with hematologic malignancies.
  • Review the safety and efficacy data from clinical trials that have evaluated bispecific T-cell engagers in patients with B-cell lymphomas and multiple myeloma.
  • Identify the toxicities associated with bispecific T-cell engagers and develop an appropriate supportive care intervention for the management of adverse events.

You may also be interested in

NCCN Guidelines® Insights - B-Cell Lymphomas, Version 6.2023

Novel targeted therapies (small molecule inhibitors, antibody–drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas.
Additional information
Supporters: 

This activity is supported through educational grants from AstraZeneca; Bristol Myers Squibb; Genentech, a member of the Roche Group; GSK; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Lilly; Novartis; Sanofi; Seagen; Servier Pharmaceuticals LLC; and Taiho Oncology, Inc. This educational activity is supported by a medical education grant from Karyopharm Therapeutics. This educational activity is supported by independent educational grants from AbbVie; Daiichi Sankyo; Incyte Corporation; and Merck & Co., Inc., Rahway, NJ, USA. This activity is supported by an unrestricted educational grant provided by Prothena Biosciences Ltd, Dublin, Ireland, a member of the Prothena Corporation plc group. This activity is supported by a grant from Pfizer Inc.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.00 Participation
Course opens: 
12/01/2023
Course expires: 
12/01/2024
Cost:
$0.00
Part of: 
Recorded Presentations from the NCCN 2023 Annual Congress: Hematologic Malignancies™

L. Elizabeth Budde, MD, PhD
City of Hope National Medical Center

Stacy Pak, PharmD, BCOP
City of Hope National Medical Center

Lauren R. Seipel, DNP, NP-C, AOCNP, BMTCN
City of Hope National Medical Center

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below has no relevant financial relationships with ineligible companies to disclose.

Stacy Pak, PharmD, BCOP

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

L. Elizabeth Budde, MD, PhD
AbbVie, Inc.: Consulting Fee
ADC Therapeutics SA: Consulting Fee 
Amgen Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support 
Kite Pharma: Consulting Fee
Merck & Co., Inc.: Grant/Research Support 
MustangBio: Grant/Research Support 
Roche Laboratories, Inc.: Consulting Fee

Lauren R. Seipel, DNP, NP-C, AOCNP, BMTCN
Genentech, Inc.: Scientific Advisor

Congress Planning Committee Disclosures

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Gabriela S. Hobbs, MD
AbbVie, Inc.: Scientific Advisor
Bristol Myers Squibb: Scientific Advisor
Cogent Biosciences, Inc.: Consulting Fee
Incyte Corporation: Grant/Research Support; Scientific Advisor
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Scientific Advisor
PharmaEssentia Corporation: Consulting Fee
Pharmaxis Ltd.: Consulting Fee
Protagonist Therapeutics Inc.: Consulting Fee
Pfizer Inc.: Consulting Fee

Shaji K. Kumar, MD
AbbVie, Inc.: Grant/Research Support; Scientific Advisor
Amgen Inc.: Grant/Research Support; Scientific Advisor
BeiGene: Honoraria
Bristol Myers Squibb: Grant/Research Support; Scientific Advisor
GSK: Grant/Research Support; Scientific Advisor
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Karyopharm Therapeutics: Grant/Research Support; Scientific Advisor
Loxo Oncology, Inc.: Scientific Advisor
Regeneron Pharmaceuticals, Inc.: Grant/Research Support; Scientific Advisor
Roche Laboratories, Inc.: Grant/Research Support; Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support; Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Grant/Research Support; Scientific Advisor

Bernard L. Marini, PharmD, BCOP
Servier Laboratories: Consulting Fee

MiKaela Olsen, DNP, APRN-CNS, AOCNS, FAAN
BD: Honoraria

Andrew D. Zelenetz, MD, PhD
AbbVie, Inc.: Consulting Fee
Adaptive Biotechnologies: Scientific Advisor
ADC Therapeutics SA: Scientific Advisor
Amgen Inc.: Consulting Fee
Arvinas: Consulting Fee; Scientific Advisor
AstraZeneca Pharmaceuticals LP: Consulting Fee
BeiGene: Consulting Fee; Grant/Research Support
Bristol Myers Squibb: Consulting Fee
Eli Lilly and Company: Consulting Fee; Scientific Advisor
Genentech, Inc.: Consulting Fee; Grant/Research Support
Gilead Sciences, Inc.: Consulting Fee
Janssen Pharmaceutica Products, LP: Consulting Fee
MEI Pharma Inc.: Consulting Fee; Grant/Research Support
MorphoSys AG: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Roche Laboratories, Inc.: Consulting Fee; Grant/Research Support

NCCN Staff Disclosures

None of the other planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour, 1.0 of which are pharmacotherapeutic contact hours.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-23-111-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until December 1, 2024. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing